Hemorheologic effects of Meclomen including effect in malignant melanoma
| Autor: | J.L. Ambrus, K. Qazi, M. Mahafzah, S. Stadler |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Platelet Aggregation
Blood viscosity Arachidonic Acids Pharmacology Platelet Factor 3 chemistry.chemical_compound Erythrocyte Deformability medicine Erythrocyte deformability Cyclooxygenase Inhibitors ortho-Aminobenzoates Platelet Lipoxygenase Inhibitors Melanoma Meclofenamic Acid Arachidonic Acid Platelet-activating factor Hematology Blood Viscosity Red blood cell medicine.anatomical_structure chemistry Immunology Meclofenamate Sodium Platelet aggregation inhibitor Collagen Platelet Aggregation Inhibitors |
| Zdroj: | Thrombosis Research. 57:925-934 |
| ISSN: | 0049-3848 |
| DOI: | 10.1016/0049-3848(90)90159-a |
| Popis: | Sodium Meclofenamate, (Meclomen) (M) is a non-steroidal anti-inflammatory drug, which inhibits both cyclooxygenases and lipooxygenases of the arachidonic acid cascade (AA). (M) inhibited adenosine diphosphosphate (ADP) induced platelet aggregation, arachidonic acid (AA) induced platelet aggregation and collagen induced platelet aggregation. (M) inhibited platelet factor 3 availability when measured by Stypven clotting time. Red cells from patients with advanced malignancies and normal red cells stored in blood banks exhibited loss of deformability. (M) enhanced red cell deformability in these blood samples. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|